SCHEMBL27609034

SCHEMBL27609034

CCCCC1CCN(CCCCN2c3ccccc3SC2C=O)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM1 P11229 13/20 0.50
▸ CHRM3 P20309 11/20 0.50
▸ CHRM2 P08172 11/20 0.50
▸ CHRM5 P08912 10/20 0.50
▸ CHRM4 P08173 9/20 0.50
▸ DRD2 P14416 8/20 0.50
▸ DRD3 P35462 8/20 0.50
▸ DRD4 P21917 7/20 0.50
▸ ADRA1A P35348 4/20 0.50
▸ ADRA1D P25100 2/20 0.50
▸ ADRA1B P35368 2/20 0.50
▸ ADRB2 P07550 2/20 0.50
▸ ADRB1 P08588 1/20 0.50
▸ HTR1A P08908 3/20 0.47
▸ ADRA2B P18089 2/20 0.47
▸ HRH1 P35367 2/20 0.47
▸ ADRA2A P08913 2/20 0.47
▸ HRH3 Q9Y5N1 2/20 0.47
▸ KCNH2 Q12809 4/20 0.44
▸ KDM1A O60341 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27590503 0.99 CHRM1 (0.49) CHRM1CHRM3CHRM2CHRM5CHRM4
SCHEMBL27590543 0.94 CHRM1 (0.48) CHRM1CHRM3CHRM2CHRM5CHRM4
SCHEMBL27590526 0.85 KDM1A (0.55) CHRM1CHRM3CHRM2CHRM5CHRM4
SCHEMBL27609108 0.78 CHRM1 (0.50) CHRM1CHRM3CHRM2CHRM5CHRM4
SCHEMBL27609010 0.78 KDM1A (0.51) CHRM1CHRM3CHRM2CHRM5CHRM4
SCHEMBL27590546 0.74 SMN1; SMN2 (0.42) MEN1KMT2A
SCHEMBL27609019 0.73 PIM1 (0.33) HDAC6
SCHEMBL27590533 0.72 HDAC3 (0.32) KDM1AHDAC6
SCHEMBL4095785 0.72 CHRM1 (0.67) CHRM1CHRM3CHRM2CHRM5CHRM4
SCHEMBL28250648 0.71 ALDH1A1 (0.38) MEN1USP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1561212-A Benzimidazolone Derivatives as Muscarinic Agents ACADIA PHARM INC (US) 2005-01-05 — — CN disclosed
Send feedback